Bionano Genomics, Inc.(BNGO)Earnings, Financials & Key Ratios

BNGO•NASDAQ

$1.14

Price updated Jul 7, 2026

SectorHealthcare IndustryDiagnostics & Research Sub-IndustryLife Science Instruments and Sequencing Tools

AboutBionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.Show more

Revenue$29M-7.4%
EBITDA-$24M+73.7%
Net Income-$26M+76.4%
EPS (Diluted)-4.85+94.5%
Gross Margin21.95%+1677.9%
EBITDA Margin-82.81%+71.6%
Operating Margin-116.95%+65.4%
Net Margin-92.59%+74.6%
ROE-66.15%+61.2%

BNGO Price & Volume

Bionano Genomics, Inc. (BNGO) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operational Losses Threaten Future Liquidity Position

Investment Thesis • Updated 2026Q1

VerdictNegative: The company's critical liquidity position

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Acute liquidity and dilution

Key Thesis Takeaways

Bionano Genomics faces a challenging outlook as its Optical Genome Mapping technology struggles to achieve commercial scale, evidenced by a consistent inability to generate positive operating income.
The company's financial health is currently strained by a rapid depletion of cash reserves and a significant erosion of its asset base, which has fallen from $214.4M in 2023Q4 to $64.8M by 2026Q1.
Investors should remain cautious regarding the firm's long-term viability, as the current trajectory of negative free cash flow and recurring dilution risks may necessitate further capital raises to sustain operations.

Verdict Logic

evidenced by a cash balance of only $2.99M as of 2025Q4, suggests a high probability of further dilutive financing that could significantly impair shareholder value.

BNGO Growth Metrics

Bionano Genomics, Inc. (BNGO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years27.37%

3 Years0.84%

TTM0.96%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM62.25%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM89.87%

Return on Capital

10 Years-160.16%

5 Years-80.17%

3 Years-106.98%

Last Year-74.11%

BNGO Recent Earnings

Bionano Genomics, Inc. (BNGO) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 5/12 qtrs (42%)●Beat Revenue 7/12 qtrs (58%)

Q2 2026Latest

May 13, 2026

Metric

Actual

Est

EPS

$0.76+13.6%

$0.88

Rev

$7M+1.8%

$7M

Q2 2026

Mar 23, 2026

Metric

Actual

Est

EPS

$0.03+96.3%

$0.81

Rev

$8M+0.9%

$8M

Q4 2025

Nov 13, 2025

Metric

Actual

Est

EPS

$1.59+12.2%

$1.81

Rev

$7M-6.7%

$8M

Q3 2025

Aug 14, 2025

Metric

Actual

Est

EPS

$1.99+26.0%

$2.69

Rev

$7M-6.8%

$7M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 13, 2026	$0.76vs $0.88+13.6%	$7Mvs $7M+1.8%
Q2 2026	Mar 23, 2026	$0.03vs $0.81+96.3%	$8Mvs $8M+0.9%
Q4 2025	Nov 13, 2025	$1.59vs $1.81+12.2%	$7Mvs $8M-6.7%
Q3 2025	Aug 14, 2025	$1.99vs $2.69+26.0%	$7Mvs $7M-6.8%

Based on last 12 quarters of dataView full earnings history →

Latest BNGO News

Recent stock market news and headlines for Bionano Genomics, Inc. (BNGO)

GlobeNewsWire·Jun 24, 2026

Bionano Announces Hiring of Chief Scientific Officer

SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific Officer (CSO), effective July 20, 2026. In this role, Dr. Hastie will lead the company's global scientific strategy, innovation roadmap, and research initiatives, advancing Bionano's mission to expand the research application of its genome analysis technologies and to develop a clinical applications strategy.

GlobeNewsWire·Jun 18, 2026

Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption

SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that studies featuring optical genome mapping (OGM) at the 2026 European Society of Human Genetics (ESHG) conference grew substantially compared to the conference in 2025, consistent with expanding global adoption of OGM. Key highlights from studies of OGM presented at ESHG 2026: 35 studies featured OGM — a 67% increase over the 21 studies reported at ESHG 2025.

Peers Comparison

Key metrics vs top competitors for Bionano Genomics, Inc. (BNGO)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
BNGOBionano Genomics, Inc.Current	$1.14	$3.74M	-0.24	-7.37%	-92.59%	-66.15%	—
PACBPacific Biosciences of California, Inc.	$1.56	$484.54M	-0.86	3.89%	-80.34%	-488.45%	—
CDNACareDx, Inc	$28.31	$1.46B	-70.78	13.79%	-1.98%	-2.61%	—
NTRANatera, Inc.	$281.27	$40.28B	-185.05	35.9%	-9.05%	-15.13%	—
ILMNIllumina, Inc.	$191.76	$29.13B	35.19	-0.78%	19.43%	32.84%	—
EXASExact Sciences Corporation	$104.91	$20.02B	-95.37	17.69%	-6.4%	-8.66%	—

Compare BNGO vs Peers

Bionano Genomics, Inc. (BNGO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PACB

Most directly comparable listed peer for BNGO.

Scale Benchmark

vs TMO

Larger-name benchmark to compare BNGO against a more recognizable public peer.

Peer Set

Compare Top 5

vs PACB, CDNA, NTRA, ILMN

BNGO SEC Filings & Documents

Bionano Genomics, Inc. (BNGO) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 14, 2026·SEC

Material company update

May 13, 2026·SEC

Material company update

May 6, 2026·SEC

10-K Annual Reports

FY 2026

Mar 23, 2026·SEC

FY 2025

Mar 31, 2025·SEC

FY 2024

Mar 5, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 13, 2026·SEC

FY 2025

Nov 13, 2025·SEC

FY 2025

Aug 14, 2025·SEC

Get notified when BNGO posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

BNGO Frequently Asked Questions

Bionano Genomics, Inc. (BNGO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Bionano Genomics, Inc.'s revenue?

Bionano Genomics, Inc. (BNGO) reported $28.7M in revenue for fiscal year 2025. This represents a 323% increase from $6.8M in 2016.

How fast is Bionano Genomics, Inc. growing?

Bionano Genomics, Inc. (BNGO) saw revenue decline by 7.4% over the past year.

Is BNGO profitable?

Bionano Genomics, Inc. (BNGO) reported a net loss of $31.6M for fiscal year 2025.

Dividend & Returns

What is BNGO's return on equity?

Bionano Genomics, Inc. (BNGO) has a return on equity (ROE) of -66.2%. Negative ROE indicates the company is unprofitable.

What is Bionano Genomics, Inc.'s free cash flow?

Bionano Genomics, Inc. (BNGO) had negative free cash flow of $19.3M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in BNGO back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 13, 2026

$0.76vs $0.88+13.6%

$7Mvs $7M+1.8%

Q2 2026

Mar 23, 2026

$0.03vs $0.81+96.3%

$8Mvs $8M+0.9%

Q4 2025

Nov 13, 2025

$1.59vs $1.81+12.2%

$7Mvs $8M-6.7%

Q3 2025

Aug 14, 2025

$1.99vs $2.69+26.0%

$7Mvs $7M-6.8%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

BNGOBionano Genomics, Inc.Current

$1.14

$3.74M

-0.24

-7.37%

-92.59%

-66.15%

—

PACBPacific Biosciences of California, Inc.

$1.56

$484.54M

-0.86

3.89%

-80.34%

-488.45%

—

CDNACareDx, Inc

$28.31

$1.46B

-70.78

13.79%

-1.98%

-2.61%

—

NTRANatera, Inc.

$281.27

$40.28B

-185.05

35.9%

-9.05%

-15.13%

—

ILMNIllumina, Inc.

$191.76

$29.13B

35.19

-0.78%

19.43%

32.84%

—

EXASExact Sciences Corporation

$104.91

$20.02B

-95.37

17.69%

-6.4%

-8.66%

—